Diaccurate is a spin off from the Pasteur Institute in Paris, France. We work on a new enzymatic mechanism involved in the control of immune responses against HIV and other pathogens. Involvement of this mechanism in the control of tumor growth is also under study. We have discovered in the plasma of immunodeficient patients, a new molecule named RIF (for “Refractory state Inducing Factor”) which by modifying their membrane blocks specifically CD4 lymphocytes responses. Inhibitory monoclonal antibody neutralizing RIF has been characterized and clinical trials should start in 2018.